EyePoint, Inc.
NASDAQEyePoint Pharmaceuticals adds a fresh Street voice this week, but the options market and a sticky short base tell a more cautious story ahead of its July 31 earnings event. The newest development is Cantor Fitzgerald's initiation on July 8, with analyst Steve Seedhouse assuming coverage at Overweight and a $47 price target. That adds a tenth buy-side voice to an already heavily…
Snapshot as of 9 Aug 2026
EyePoint Pharmaceuticals adds a fresh Street voice this week, but the options market and a sticky short base tell a more cautious story ahead of its July 31 earnings event. The newest development is Cantor Fitzgerald's…
EyePoint Pharmaceuticals heads into July with a sharp analyst upgrade colliding against a short base that refuses to budge — a tension that defines the stock's setup heading into its July 31 earnings event. The most…
EyePoint Pharmaceuticals has bounced 11.6% this week to $14.38, yet the persistent weight of heavy short positioning and a notable shift in options sentiment means this recovery is happening against an unconvinced…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for EYPT — free to start on ORTEX.
Sign up for free →Open EYPT on ORTEX